# Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

> **NCT02544308** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University College, London** · enrollment: 36 (actual)

## Conditions studied

- Plasmacytoma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **OTHER:** No further treatment

## Key facts

- **NCT ID:** NCT02544308
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-03-10
- **Primary completion:** 2026-04
- **Final completion:** 2026-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-12-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02544308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02544308, "Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02544308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*